Drugs / EpiVacCorona
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04527575 | Jul 2020 → Dec 2021 | COVID-19 | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04780035 | Nov 2020 → Aug 2021 | COVID-19 | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | Completed | No outcome recorded |
| Phase 3 | NCT05021016 | Nov 2020 → Jan 2021 | COVID-19 | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EpiVacCorona | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04780035 ↗ |
| Known as | EpiVacCorona vaccine | “The EpiVacCorona vaccine is intended to prevent COVID-19.” NCT04780035 ↗1“The EpiVacCorona vaccine is intended to prevent COVID-19.” NCT05021016 ↗ |
| Modality | Vaccine | “EpiVacCorona vaccine is intended to prevent COVID-19.” NCT04527575 ↗ |
| Route | Intramuscular | “when administered twice intramuscularly” NCT04527575 ↗ |